Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "Yes, the licensing can continue."

There are two separate issues --- the $1 million note payable in default and, much more importantly, the dispute over the mechanics of the commercialization agreement and the management of PDS going forward. There are potentially many, many millions at stake with respect to the second issue. We better get it right.

Share
New Message
Please login to post a reply